

# Monica Balzarotti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9415315/publications.pdf>

Version: 2024-02-01

102  
papers

4,454  
citations

159585

30  
h-index

106344

65  
g-index

105  
all docs

105  
docs citations

105  
times ranked

4003  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. <i>Lancet, The</i> , 2009, 374, 1512-1520.   | 13.7 | 588       |
| 2  | Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology,the</i> , 2016, 3, e217-e227.  | 4.6  | 442       |
| 3  | Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group. <i>Journal of Clinical Oncology</i> , 2003, 21, 20-27.   | 1.6  | 420       |
| 4  | Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology,the</i> , 2017, 4, e510-e523. | 4.6  | 258       |
| 5  | Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma. <i>Haematologica</i> , 2007, 92, 35-41.  | 3.5  | 216       |
| 6  | First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 2766-2772.   | 1.6  | 190       |
| 7  | Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD.. <i>Journal of Clinical Oncology</i> , 1997, 15, 528-534.  | 1.6  | 171       |
| 8  | [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography Predicts Survival After Chemoimmunotherapy for Primary Mediastinal Large B-Cell Lymphoma: Results of the International Extranodal Lymphoma Study Group IELSG-26 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 1769-1775.  | 1.6  | 149       |
| 9  | Induction chemotherapy strategies for primary mediastinal large B-cell lymphoma with sclerosis: a retrospective multinational study on 426 previously untreated patients. <i>Haematologica</i> , 2002, 87, 1258-64.  | 3.5  | 141       |
| 10 | Modulated Chemotherapy According to Modified Comprehensive Geriatric Assessment in 100 Consecutive Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Oncologist</i> , 2012, 17, 838-846.   | 3.7  | 114       |
| 11 | Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy. <i>Haematologica</i> , 2012, 97, 1073-1079.   | 3.5  | 108       |
| 12 | Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2017, 18, 1076-1088.  | 10.7 | 100       |
| 13 | Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 1530-1542.   | 10.7 | 91        |
| 14 | MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. <i>Neurology</i> , 2006, 66, 1435-1438.  | 1.1  | 83        |
| 15 | Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021, 39, 1214-1222.   | 1.6  | 74        |
| 16 | High-Dose Chemotherapy in Poor-Prognosis Adult Small Round-Cell Tumors: Clinical and Molecular Results From a Prospective Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 2181-2188.  | 1.6  | 71        |
| 17 | The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). <i>Annals of Oncology</i> , 2014, 25, 442-447.   | 1.2  | 67        |
| 18 | Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. <i>Haematologica</i> , 2012, 97, 416-422.   | 3.5  | 61        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: The Milan Cancer Institute Experience. <i>Annals of Oncology</i> , 1993, 4, 831-837.  | 1.2 | 58        |
| 20 | Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , 2021, 35, 787-795.  | 7.2 | 56        |
| 21 | Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy. <i>British Journal of Haematology</i> , 2009, 145, 369-372.   | 2.5 | 51        |
| 22 | The prognostic value of positron emission tomography performed after two courses (<sc>INTERIM-PET</sc>) of standard therapy on treatment outcome in early stage <sc>H</sc>odgkin lymphoma: A multicentric study by the fondazione italiana linfomi (FIL). <i>American Journal of Hematology</i> , 2015, 90, 499-503. | 4.1 | 49        |
| 23 | Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. <i>Leukemia</i> , 2022, 36, 1870-1878.   | 7.2 | 47        |
| 24 | Nonmyeloablative conditioning, unmanipulated haploidentical SCT and post-infusion CY for advanced lymphomas. <i>Bone Marrow Transplantation</i> , 2014, 49, 1475-1480.   | 2.4 | 41        |
| 25 | MATILDE chemotherapy regimen for primary CNS lymphoma. <i>Neurology</i> , 2014, 82, 1370-1373.   | 1.1 | 38        |
| 26 | Initial chemotherapy for primary resectable large-cell lymphoma of the stomach. <i>Annals of Oncology</i> , 1997, 8, 497-499.  | 1.2 | 36        |
| 27 | Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients. <i>Annals of Hematology</i> , 2012, 91, 1013-1022.   | 1.8 | 36        |
| 28 | PCR-based clonality analysis: a reliable method for the diagnosis and follow-up monitoring of conservatively treated gastric B-cell MALT lymphomas?. <i>Histopathology</i> , 1999, 34, 326-330.  | 2.9 | 34        |
| 29 | Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. <i>Hematological Oncology</i> , 2018, 36, 68-75.  | 1.7 | 34        |
| 30 | Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: A phase II randomized study. <i>Annals of Oncology</i> , 2000, 11, 231-233.  | 1.2 | 32        |
| 31 | Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 42-49.                    | 0.8 | 31        |
| 32 | Prospective study of high-dose chemotherapy and autologous peripheral stem cell transplantation in adult patients with advanced desmoplastic small round-cell tumour. <i>British Journal of Cancer</i> , 2003, 89, 1159-1161.  | 6.4 | 29        |
| 33 | Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e34-e44.   | 4.6 | 29        |
| 34 | Dose-escalation of CHOP in non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1999, 10, 519-526.  | 1.2 | 28        |
| 35 | Soluble interleukin-2 receptors (sIL-2R) in Hodgkin's disease: outcome and clinical implications. <i>British Journal of Cancer</i> , 1998, 77, 992-997.  | 6.4 | 27        |
| 36 | Comprehensive Geriatric Evaluation in Elderly Patients With Lymphoma: Feasibility of a Patient-Tailored Treatment Plan. <i>Journal of Clinical Oncology</i> , 2003, 21, 754-754.   | 1.6 | 27        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study. <i>American Journal of Hematology</i> , 2007, 82, 122-127.   | 4.1 | 27        |
| 38 | Allogeneic Stem Cell Transplantation Compared with Chemotherapy for Poor-Risk Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 432-438.  | 2.0 | 26        |
| 39 | Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. <i>Annals of Oncology</i> , 2002, 13, 1341-1346.  | 1.2 | 24        |
| 40 | Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. <i>European Journal of Haematology</i> , 2007, 78, 322-329.  | 2.2 | 24        |
| 41 | Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma. <i>Annals of Oncology</i> , 1996, 7, 970-972.   | 1.2 | 20        |
| 42 | Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. <i>Bone Marrow Transplantation</i> , 2001, 28, 923-927.  | 2.4 | 20        |
| 43 | IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. <i>Bone Marrow Transplantation</i> , 2007, 40, 1019-1025.   | 2.4 | 20        |
| 44 | The 68 Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf  | 0.7 | 20        |
| 45 | Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial. <i>British Journal of Haematology</i> , 2022, 196, 1184-1193.  | 2.5 | 19        |
| 46 | Feasibility and toxicity of high-dose therapy (HDT) supported by peripheral blood stem cells in elderly patients with multiple myeloma and non-Hodgkin's lymphoma: Survey from a single institution. <i>American Journal of Hematology</i> , 2003, 73, 267-272.  | 4.1 | 17        |
| 47 | Tandem autologous-allo-SCT is feasible in patients with high-risk relapsed non-Hodgkin's lymphoma. <i>Bone Marrow Transplantation</i> , 2013, 48, 249-252.   | 2.4 | 15        |
| 48 | Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network. <i>Hematological Oncology</i> , 2019, 37, 160-167.  | 1.7 | 15        |
| 49 | Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: A REL (Rete Ematologica Lombarda) experience. <i>Leukemia Research</i> , 2011, 35, 712-714.   | 0.8 | 14        |
| 50 | Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. <i>Blood</i> , 2016, 128, 511-511. | 1.4 | 13        |
| 51 | Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice. <i>Oncologist</i> , 2019, 24, 1246-1252.  | 3.7 | 10        |
| 52 | Definition and Validation of the New Elderly Prognostic Index (EPI) for Elderly Patients with Diffuse Large B-Cell Lymphoma Integrating Geriatric and Clinical Assessment: Results of the Prospective "Elderly Project" on 1353 Patients By the Fondazione Italiana Linfomi. <i>Blood</i> , 2019, 134, 398-398.  | 1.4 | 10        |
| 53 | Reduced intensity conditioning regimen followed by glycosylated G-CSF mobilized PBST in patients with solid tumors and malignant lymphomas. <i>Bone Marrow Transplantation</i> , 2002, 30, 207-214.  | 2.4 | 9         |
| 54 | High-dose melphalan with autologous stem cell support in refractory Hodgkin lymphoma patients as a bridge to second transplant. <i>Bone Marrow Transplantation</i> , 2015, 50, 499-504.  | 2.4 | 9         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Letter to the Editor. <i>Leukemia and Lymphoma</i> , 2003, 44, 1439-1440.   | 1.3 | 8         |
| 56 | Tandem autologous-allogeneic stem cell transplantation as a feasible and effective procedure in high-risk lymphoma patients. <i>Haematologica</i> , 2015, 100, e423-e427.   | 3.5 | 7         |
| 57 | B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2016, 57, 2375-2381. | 1.3 | 7         |
| 58 | Factors Affecting Outcome of Patients with Refractory/Relapsed Hodgkin's Disease (HD) Treated with IGEV Chemotherapy (CT) and High Dose Consolidation Therapy (HDT) with Stem Cell Rescue.. <i>Blood</i> , 2005, 106, 2091-2091.  | 1.4 | 7         |
| 59 | Therapeutic and Mobilizing Activity of a Vinorelbine, Ifosfamide and Cytarabine Regimen (VIHA) as Salvage Regimen In Resistant/Relapse Non Hodgkin Lymphoma (NHL). <i>Blood</i> , 2010, 116, 1761-1761.   | 1.4 | 7         |
| 60 | CD34 dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. <i>European Journal of Haematology</i> , 2007, 78, 111-116.   | 2.2 | 6         |
| 61 | Single-agent high-dose melphalan followed by peripheral blood stem cell (PBSC) in lymphoma patients: an effective, and well-tolerated conditioning regimen. <i>Bone Marrow Transplantation</i> , 2004, 33, 1067-1068.   | 2.4 | 5         |
| 62 | Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?. <i>Annals of Translational Medicine</i> , 2020, 8, 1035-1035.   | 1.7 | 5         |
| 63 | Primary Diffuse Large B-Cell Lymphoma of the Testis (PTL): A Prospective Study of Rituximab (R)-CHOP with CNS and Contralateral Testis Prophylaxis. Results of the IELSG 10 Study.. <i>Blood</i> , 2006, 108, 208-208.  | 1.4 | 5         |
| 64 | Primary mediastinal B-cell lymphoma with sclerosis: Report of 11 cases treated with intensified-CHOP plus radiotherapy. <i>American Journal of Hematology</i> , 2005, 78, 312-313.  | 4.1 | 4         |
| 65 | MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL). <i>HemaSphere</i> , 2019, 3, e305.   | 2.7 | 4         |
| 66 | A brief rituximab, bendamustine, mitoxantrone (R <sup>2</sup> BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021, 193, 280-289.   | 2.5 | 4         |
| 67 | A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. <i>Investigational New Drugs</i> , 2021, 39, 1028-1035.                      | 2.6 | 4         |
| 68 | IHP Interpretation Criteria of Interim-PET Scan Confirms Prognostic Impact In Early Stage Hodgkin Lymphoma Patients without Bulky Disease. <i>Blood</i> , 2010, 116, 3890-3890.   | 1.4 | 4         |
| 69 | What is the Best Option to Cure Patients with Resistant/Relapsing Hodgkins Disease?. <i>Current Stem Cell Research and Therapy</i> , 2006, 1, 419-424.  | 1.3 | 4         |
| 70 | Intensified CHOP in non-Hodgkin's lymphoma: What we know and what we need to know. <i>Annals of Oncology</i> , 1999, 10, 875-876.   | 1.2 | 3         |
| 71 | Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. <i>Annals of Oncology</i> , 2006, 17, 533.   | 1.2 | 3         |
| 72 | The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. <i>American Journal of Hematology</i> , 2015, 90, 56-61.        | 4.1 | 3         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers. <i>Blood</i> , 2010, 116, 966-966.  | 1.4 | 3         |
| 74 | Study of the HLA-DP1 Locus by the Polymerase Chain Reaction Technique in Patients with Hodgkin's Disease. <i>Tumori</i> , 1993, 79, 133-136.  | 1.1 | 2         |
| 75 | Dose-Adjusted EPOCH and Rituximab (DA-EPOCH-R) Treatment in Dual Expressor Diffuse Large B-Cell and Double/Triple Hit Lymphomas: TP53 Mutations Influence on Clinical Outcome. <i>Blood</i> , 2019, 134, 4116-4116.   | 1.4 | 2         |
| 76 | Role of Positron Emission Tomography (PET/CT) in Primary Mediastinal Large B Cell Lymphoma (PMLBCL): Preliminary Results of an International Phase II Trial (IELSG-26 Study) Conducted On Behalf of the International Extranodal Lymphoma Study Group (IELSG), the Fondazione Italiana Linfomi (FIL) and the UK NCRI Lymphoma Group. <i>Blood</i> , 2012, 120, 1566-1566. | 1.4 | 2         |
| 77 | The Elderly Project By the Fondazione Italiana Linfomi (FIL): A Prospective Multidimensional Assessment of Elderly Patients with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2016, 128, 3049-3049.  | 1.4 | 2         |
| 78 | Pharmacogenomics Drives Lenalidomide Efficacy and MRD Kinetics in Mantle Cell Lymphoma after Autologous Transplantation: Results from the MCL0208 Multicenter, Phase III, Randomized Clinical Trial from the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2020, 136, 16-17.  | 1.4 | 2         |
| 79 | Small lymphocytic lymphoma in true trilineage hematopoietic tissue within heterotopic ossification in an enucleated blind painful eye: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 92.  | 0.8 | 1         |
| 80 | Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi. <i>Annals of Hematology</i> , 2021, 100, 2547-2556.   | 1.8 | 1         |
| 81 | Rituximab with Dose-Adjusted EPOCH (R-DA-EPOCH) with or without Autologous Stem Cell Transplantation (ASCT) As First Line Treatment in Patients with Aggressive B-Cell Lymphoma with <i>MYC</i> and <i>BCL-2</i> and/or <i>BCL-6</i> Gene Rearrangements or Increase Copy Number. <i>Blood</i> , 2020, 136, 38-39.  | 1.4 | 1         |
| 82 | Comprehensive Geriatric Assessment-Adapted Chemotherapy in 100 Elderly Patients (>70 Years) with Diffuse Large B-Cell Non-Hodgkin's Lymphoma (DLBCL). <i>Blood</i> , 2006, 108, 2440-2440.  | 1.4 | 1         |
| 83 | Brief Chemoimmunotherapy Rituximab, Bendamustine, Mitoxantrone (R-BM) Followed by Rituximab Consolidation in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): Preliminary Results of a Prospective Phase II Study by Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012, 120, 2720-2720.  | 1.4 | 1         |
| 84 | Non-Hodgkin's Lymphomas Associated With Positive Hepatitis-C Virus Infection: A Prospective Multicentric Observational Study On Behalf Of The "Rete Ematologica Lombarda/Hematology Network Of Lombardia Region". <i>Blood</i> , 2013, 122, 3003-3003.  | 1.4 | 1         |
| 85 | Early restaging positron emission tomography with 18F-fluorodeoxyglucose in aggressive non-Hodgkin's lymphomas: is it too easy to be true?. <i>Annals of Oncology</i> , 2003, 14, 1155-1156.  | 1.2 | 0         |
| 86 | High relapse rate after a brief chemotherapy course and involved-field radiotherapy in early-stage Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2007, 48, 2444-2446.  | 1.3 | 0         |
| 87 | Diagnosis and Treatment of Hodgkin's Lymphoma. , 2013, , 985-1013.  |     | 0         |
| 88 | Efficacy and Feasibility of DA-EPOCH-R in Aggressive B-Cell Lymphoma: A Real Life Single-Center Analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S250.  | 0.4 | 0         |
| 89 | Risk-tailored treatment of splenic marginal zone lymphoma. <i>Anti-Cancer Drugs</i> , 2021, Publish Ahead of Print, .   | 1.4 | 0         |
| 90 | Positron Emission Tomography Status and Tandem High-Dose Therapy Favorably Influence Outcome of Patients with Relapsed and/or Refractory Hodgkin Lymphoma. <i>Blood</i> , 2011, 118, 335-335.   | 1.4 | 0         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi. Blood, 2011, 118, 2636-2636.  | 1.4 | 0         |
| 92  | Autologous Transplantation Followed by Reduced-Intensity Allogeneic Transplantation Is Feasible in Patients with High-Risk Non-Hodgkin's Lymphoma. Blood, 2011, 118, 3105-3105.  | 1.4 | 0         |
| 93  | R-CHOP21 Vs R-CHOP14 in 950 Diffuse Large B-Cell Lymphoma Patients: Results of a Multicentre Retrospective Study Form Italian Lymphoma Foundation (FIL). Blood, 2012, 120, 1615-1615.  | 1.4 | 0         |
| 94  | What Is the Best Combination of First-Line and Salvage Treatments in Follicular Lymphoma? Results of the Multicenter Study "Refol" by the Fondazione Italiana Linfomi (FIL) On 548 Patients. Blood, 2012, 120, 154-154.  | 1.4 | 0         |
| 95  | Non Pegilated Liposomal Doxorubicin (TLC-D99; Myocet ®, ©) Can Be Safely and Effectively Used As Part of the R-COMP Regimen in Patients with Diffuse Large B-Cell Lymphoma Who Show Contraindications to Anthracyclines Due to Concomitant Moderate/Severe Heart Disease. Results of the HEART01 Phase II trial by the Fondazione Italiana Linfomi (NCT01009970). Blood, 2012, 120, 3644-3644. | 1.4 | 0         |
| 96  | Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi. Blood, 2013, 122, 5088-5088.  | 1.4 | 0         |
| 97  | Updated results of the FOLL05 phase III trial from the Fondazione Italiana Linfomi comparing R-CVP, R-CHOP, and R-FM in patients with advanced follicular lymphoma.. Journal of Clinical Oncology, 2014, 32, 8530-8530.  | 1.6 | 0         |
| 98  | Feasibility and Efficacy of Tandem Autologous-Allogeneic Transplantation in a Cohort of 111 Patients Affected By High-Risk Hodgkin's and Non-Hodgkin's Lymphoma. Blood, 2014, 124, 3863-3863.  | 1.4 | 0         |
| 99  | Autologous Stem Cell Transplantation Followed By Allogeneic SCT Provides Promising Results in Patients with Relapsed DLBCL and Adverse Prognostic Features Compared with ASCT Alone. Blood, 2015, 126, 2034-2034.  | 1.4 | 0         |
| 100 | The Addition of Bortezomib to R-DHAP Does Not Improve the Response Pre-Stem Cell Transplantation Compared to Standard R-DHAP in Young Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Results of the Phase II Randomized Trial FIL-VERAL12 of the Fondazione Italiana Linfomi. Blood, 2019, 134, 2025-2025.   | 1.4 | 0         |
| 101 | CNS Prophylaxis: How Far Is Routine Practice From the Guidelines? Focus on a Nationwide Survey by the Fondazione Italiana Linfomi (FIL). Frontiers in Oncology, 2021, 11, 730194.  | 2.8 | 0         |
| 102 | Erratum to checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?. Annals of Translational Medicine, 2020, 8, 1474-1474.   | 1.7 | 0         |